9937 HTC Readiness – A Global Perspective Podcast 1
-- Please Select --PhysicianPhD/ResearcherTechnician/Scientist/TechnologistRN, APRN, or Physician AssistantStudent/ResidentPost-Doctoral FellowSocial WorkerGenetic CounselorPhysical Therapist/Occupational TherapistHealth Business/Medical Administration ProfessionalHealth Care RegulatorPharmacistOther - specify
2. If Other, please specify: *This question is required.	
-- Please Select --Thrombosis/ClottingBleeding disorders including hemophiliaThrombosis & hemophiliaHematologyHematology/OncologyInternal medicineGeneticsRehabilitationOther - clinical-specifyOther - non-clinical-specify
3. What is your role in the care of individuals with hemophilia? Select all that apply *This question is required.	
Physician involved in direct patient care (management and monitoring of bleeding risk)
Investigator in clinical trials of patients with hemophilia
Perform assays/assessments in a specialized coagulation laboratory
Physical, occupational, and/or mental health therapy
Basic research related to hemophilia, but not related to patient care
5. How many of your patients are being managed for hemophilia each week? *This question is required.	
6. Please rate your KNOWLEDGE of the considerations for hemophilia treatment centers in anticipation of the availability of gene therapy for patients with hemophilia:
BEFORE this educational activity:	
BEFORE this educational activity:: 0 Not relevant BEFORE this educational activity:: 1 Low BEFORE this educational activity:: 2 BEFORE this educational activity:: 3 BEFORE this educational activity:: 4 BEFORE this educational activity:: 5 High
AFTER this educational activity:	
AFTER this educational activity:: 0 Not relevant AFTER this educational activity:: 1 Low AFTER this educational activity:: 2 AFTER this educational activity:: 3 AFTER this educational activity:: 4 AFTER this educational activity:: 5 High
7. Please rate your ABILITY to provide education to patients and peers about the pre- and post-infusion requirements for dosing and managing patients who undergo gene therapy. *This question is required.	
-- Please Select --Yes*I’m possibly considering changes*This activity affirms what I already do in practiceNo, I do not intend to make any changes
9. *If yes or possibly considering changes, please check off what you intend to do differently or incorporate into your clinical practice as a result of this educational activity.	
Discuss considerations for HTC gene therapy readiness with peers and colleagues
Stay up-to-date with new developments related to the administration and management of gene therapy
Anticipate the follow-up needs and monitoring for patients who undergo hemophilia gene therapy
Develop educational resources addressing HTC readiness for members of the hemophilia care team
9. If you answered no, why not:	
9. Please provide a specific way in which this activity will impact your patient care. *This question is required.	
11. Did this educational activity meet your learning needs?	
12. What educational topics would you like to see addressed in future activities? *This question is required.	
13. Was this activity scientifically sound and free of commercial bias or influence? *This question is required.	
14. If “No” please explain:	
14. FOR EUROPEAN UNION AND UNITED KINGDOM LEARNERS ONLY:
The France Foundation would like to send you educational opportunities relevant to your practice, emailed to the address you provided. May we have your consent?	